It is axiomatic that the patent system will change as a result of the current global pandemic. Countries have already rewritten patent exclusivities to assure greater access for their citizens to life-saving treatments for COVID-19.As I detailed in my April 23 column, these changes have included expanded compulsory-license and gray-market-import rights for patented drugs. Present data exclusivities over clinical test data will undoubtedly follow suit. (See my Aug. 12 column.) One additional change that we need to consider …